Literature DB >> 7654228

Cyclin A and Cdk2 kinase activity are suppressed by combined treatment with tumor necrosis factor-alpha and interferon-alpha.

K Satomoto1, M Haisa, Y Naomoto, N Tanaka, K Orita.   

Abstract

We previously reported that combined treatment with tumor necrosis factor-alpha (TNF-alpha) and interferon-alpha (IFN-alpha) showed a synergistic antitumor effect via regulation of cell cycle progression in the S phase. Here, we investigated the effect of the combined treatment with TNF-alpha and IFN-alpha on cell cycle regulating protein in RPMI 4788 cells. Treatment with TNF-alpha or IFN-alpha alone showed no effect on these proteins, however, the combined treatment showed suppression of cyclin A protein and its associated kinase activity. Furthermore, although the combined treatment inhibited Cdk2 kinase activity, the amount of Cdk2 protein was not affected. These results suggested that TNF-alpha and IFN-alpha work together to suppress cyclin A and Cdk2 kinase activity and to inhibit cell cycle progression in the S phase.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7654228     DOI: 10.1006/bbrc.1995.2242

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  3 in total

1.  The inhibitor of cyclin-dependent kinases, olomoucine II, exhibits potent antiviral properties.

Authors:  Jitka Holcakova; Peter Tomasec; Joachim J Bugert; Eddie Cy Wang; Gavin Wg Wilkinson; Roman Hrstka; Vladimir Krystof; Miroslav Strnad; Borivoj Vojtesek
Journal:  Antivir Chem Chemother       Date:  2010-01-05

2.  Roscovitine inhibits activation of promoters in herpes simplex virus type 1 genomes independently of promoter-specific factors.

Authors:  Prerna Diwan; Jonathan J Lacasse; Luis M Schang
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

3.  Effect of 5-fluorouracil on cell cycle regulatory proteins in human colon cancer cell line.

Authors:  H Takeda; M Haisa; Y Naomoto; R Kawashima; K Satomoto; T Yamatuji; N Tanaka
Journal:  Jpn J Cancer Res       Date:  1999-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.